April 29, 2017
Recommended Topic Related To:

Terbutaline Sulfate

"The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a hi"...


Terbutaline Sulfate

How Supplied


Terbutaline sulfate injection is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.


Vials should be used only for subcutaneous administration and not intravenous infusion. Sterility and accurate dosing cannot be assured if the vials are not used in accordance with DOSAGE AND ADMINISTRATION.

Discard unused portion after single patient use.

The usual subcutaneous dose of terbutaline sulfate injection is 0.25 mg injected into the lateral deltoid area. If significant clinical improvement does not occur within 15 to 30 minutes, a second dose of 0.25 mg may be administered. If the patient then fails to respond within another 15 to 30 minutes, other therapeutic measures should be considered. The total dose within 4 hours should not exceed 0.5 mg.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


Terbutaline Sulfate Injection, USP is available in a 1 mL single dose clear glass vials as follows:

NDC Number Terbutaline Sulfate Injection, USP Vial/Package Size
0703-1271-04 1 mg/mL (0.25 mL of solution will provide the usual clinical dose of 0.25 mg) 1 mL single dose vial 25 per shelf tray

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from light by storing vials in original carton until dispensed.

Do not use if solution is discolored.

Discard unused portion after single patient use.

Issued: February 2004. SICOR Pharmaceuticals, Inc. Irvine, CA 92618. FDA Rev date: n/a

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 5/28/2008

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Allergies & Asthma

Improve treatments & prevent attacks.